| Not Yet Recruiting | Tongji NADs Cohort NCT07333196 | Tongji Hospital | — |
| Not Yet Recruiting | A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Ther NCT07341828 | Huashan Hospital | Phase 1 |
| Not Yet Recruiting | hUC-MSC-Exo Therapy for Autoimmune Encephalitis NCT07131683 | Xuanwu Hospital, Beijing | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Antibody-Associated Psychiatric Disease NCT07093333 | Arialys Australia Pty Ltd | Phase 2 |
| Recruiting | Study of Pathogenic Mechanisms and Identification of Novel Autoantibodies in Autoimmune Encephalitis NCT07477015 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD1 NCT06939166 | Tianjin Huanhu Hospital | EARLY_Phase 1 |
| Active Not Recruiting | Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants NCT06753955 | Arialys Therapeutics | Phase 1 |
| Not Yet Recruiting | A Multicentric Cohort of Autoimmune Encephalitis NCT06760091 | Xuanwu Hospital, Beijing | — |
| Completed | Long-term Impact of NMDAR Encephalitis NCT06609044 | Hospices Civils de Lyon | — |
| Recruiting | Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis) NCT06584045 | Tongji Hospital | N/A |
| Active Not Recruiting | Phase 1 Study of ART5803 in Healthy Participants NCT06575153 | Arialys Therapeutics | Phase 1 |
| Recruiting | Biomarkers in Autoimmune Disease of Nervous System NCT06502015 | Tongji Hospital | — |
| Not Yet Recruiting | Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment NCT06456736 | Central South University | — |
| Recruiting | Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism NCT06079294 | Assistance Publique - Hôpitaux de Paris | N/A |
| Active Not Recruiting | Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS NCT06432803 | Hospices Civils de Lyon | — |
| Unknown | Predicting and Monitoring Outcomes in Autoimmune Encephalitis NCT05711563 | Royal College of Surgeons, Ireland | — |
| Completed | Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis NCT06033846 | Xijing Hospital | Phase 2 |
| Recruiting | Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research NCT04806620 | Brain Inflammation Collaborative | — |
| Recruiting | FDG-PET in the Diagnosis of Autoimmune Encephalitis NCT06019975 | University of Milano Bicocca | — |
| Unknown | Validation of a Diagnostic Score for Encephalitis to Assess the Risk of Autoimmune Origin NCT05953974 | Hospices Civils de Lyon | — |
| Active Not Recruiting | Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroin NCT07145502 | Biocells Medical | — |
| Completed | BRIEF TITLE * (in English and Sufficiently Descriptive) Role of MRI in Anti-LGI1 Encephalitis NCT05825690 | Hospices Civils de Lyon | — |
| Completed | Clinical Characteristics of Patients With Anti-Collapsin Response Mediator Protein 2 Antibodies in Encephaliti NCT07036042 | Nanfang Hospital, Southern Medical University | — |
| Unknown | Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis NCT05280600 | King's College London | — |
| Recruiting | A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis NCT06173076 | Shen Chun-Hong | — |
| Recruiting | The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis NCT04372615 | University of Utah | Phase 2 |
| Unknown | Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis NCT05177939 | Nihon Pharmaceutical Co., Ltd | Phase 3 |
| Recruiting | Characterization of Immune-response in Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes NCT05772611 | Hospices Civils de Lyon | — |
| Active Not Recruiting | New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes NCT05728931 | Hospices Civils de Lyon | — |
| Completed | Long-term Follow up of Patient With Anti-GABAbr Antibodies Associated-encephalitis. NCT05741619 | Hospices Civils de Lyon | — |
| Completed | Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient NCT05645185 | Hospices Civils de Lyon | — |
| Completed | Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies NCT05783947 | Hospices Civils de Lyon | — |
| Unknown | HLA Analysis in Autoimmune Encephalitis and Related Disorders: Part II NCT04823728 | Hospices Civils de Lyon | — |
| Unknown | GWAS in NMDAR Encephalitis NCT05225883 | Hospices Civils de Lyon | — |
| Recruiting | National, Multicentric Registry Study on Neuroimmunological Diseases in China NCT06443333 | Xuanwu Hospital, Beijing | — |
| Completed | CPI Combination Therapy for Autoimmune Encephalitis NCT03542279 | Xuanwu Hospital, Beijing | N/A |
| Recruiting | Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the N NCT04561557 | Tongji Hospital | EARLY_Phase 1 |
| Recruiting | Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis NCT03993262 | Jena University Hospital | Phase 2 |
| Unknown | Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis NCT04339127 | Hospices Civils de Lyon | — |
| Completed | Neuro-ophthalmology and Autoimmune Encephalitis (NODE) NCT03872284 | Hospices Civils de Lyon | — |
| Completed | Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis: NCT04175522 | Green Cross Corporation | Phase 2 |
| Unknown | HLA Analysis in Autoimmune Encephalitis and Related Disorders NCT04106596 | Hospices Civils de Lyon | — |
| Completed | Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden NCT04708626 | Uppsala University | — |
| Unknown | Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis NCT03957616 | Hospices Civils de Lyon | — |
| Terminated | Efficacy of Ocrelizumab in Autoimmune Encephalitis NCT03835728 | University of Texas Southwestern Medical Center | Phase 2 |
| Unknown | Acute Sympotomatic Seizure Secondary to Autoimmune Encephalitis and Autoimmune-associated Epilepsy NCT05422664 | Liu Yonghong | — |
| Recruiting | IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2 NCT03194815 | University of Cambridge | Phase 2 |
| Completed | Mechanisms of Auto-immune Encephalitis NCT02905136 | Hospices Civils de Lyon | — |
| Completed | To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-m NCT03530462 | First Affiliated Hospital of Zhejiang University | — |
| Withdrawn | Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients NCT03004209 | Seoul National University Hospital | Phase 4 |